This site provides valuable information about VIRAMUNE and how to help your HIV-positive patients understand and cope with their disease.
VIRAMUNE is the brand name for nevirapine (NVP), a non-nucleoside reverse transcriptase inhibitor (NNRTI), with activity against human immunodeficiency virus type 1 (HIV-1). VIRAMUNE is structurally a member of the dipyridodiazepinone chemical class of compounds. Available since 1996, VIRAMUNE was the first antiretroviral agent from the NNRTI class.
Indications and usage
Viramune® (nevirapine) is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on one principal clinical trial (BI 1090) that demonstrated prolonged suppression of HIV-RNA and two smaller supportive studies, one of which (BI 1046) is described in Full Prescribing Information.
Additional important information regarding the use of VIRAMUNE for the treatment of HIV-1 infection:
- Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled studies, VIRAMUNE should not be initiated in adult females with CD4+ cell counts greater than 250 cells/mm3 or in adult males with CD4+ cell counts greater than 400 cells/mm3 unless the benefit outweighs the risk (see WARNINGS).
- The 14-day lead-in period with VIRAMUNE 200 mg daily dosing has been demonstrated to reduce the frequency of rash (see WARNINGS and DOSAGE AND ADMINISTRATION).
Please consult Full Prescribing Information, including boxed WARNING, Medication Guide, and Important Safety Information for VIRAMUNE.
